Life Technologies Corp. v. Promega Corp.
Life Technologies Corp. v. Promega Corp., 14-1538
In an infringement suit in which plaintiff sublicensed a patent, which claims a toolkit for genetic testing, for the manufacture and sale of the kits for use in certain licensed law enforcement fields worldwide, alleging a violation of section 271(f)(1) of the Patent Act, which prohibits the supply from the United States of ‘all or a substantial portion of the components of a patented invention’ for combination abroad, the Federal Circuit’s judgment, which determined that a single important component could constitute a substantial portion’ of the components of an invention under section 271(f)(1), is reversed where the supply of a single component of a multicomponent invention for manufacture abroad does not give rise to section 271(f)(1) liability.
- Published 2017/02/22
- United States Supreme Court